Etude : XPO1 / XPO 1



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Type d'étude
MÀJ
Présentation de l'étude
Acronyme : XPO1

Nom : XPO 1

Traitement :

Type d'étude : Qualité de vie / Observationnelle

Dernière MÀJ : 24/01/2020
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C81 - Lymphome de Hodgkin
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : Detailed Description:
A research team of Centre Henri Becquerel recently detected an unexpected recurrent point mutation of XPO1 (exportin 1) (also known as Chromosome Region Maintenance 1) located in exon 15 (c.1711G>A) leading to the Glu571Lys (p.E571K) missense substitution in relapsed/refractory (R/R) Primary Mediastinal Large B-cell Lymphoma (PMBL) patients included in the LYSA LNH03 trial program and in classical Hodgkin's Lymphoma patients. It was found recurrent XPO1 E571K mutations in a large cohort of 94 patients with classical Hodgkin's lymphoma. This observation is new and could add new information on driver events and tumorigenesis in this disease. In total, 24.2 % of the patients with classical Hodgkin's lymphoma harbored the XPO1 E571K mutation. It is remarkable that 29% of all XPO1 mutations were only found in the plasma but not in the tumor because of the well-known tumor cell sparsity in Hodgkin's lymphoma. In this particular disease, highly sensitive techniques like digital Polymerase Chain Reaction and targeted Next-Generation Sequencing are essential to highlight low frequency mutations. The research team of the Centre Henri Becquerel have identified a trend toward unfavorable prognostic impact in terms of progression-free survival in patients with detectable XPO1 E571K mutation in plasma cell-free DNA at the end of treatment, which could prove to be statistically significant in a larger cohort. It was observed that 57% of patients who ultimately relapsed were positive in the plasma after end of therapy. It remains to be established whether this mutation adds new relevant value as compared to Positron Emission Tomography-scan.

Phase : NA

Stade : NA

1
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : Age ≥18 years
Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma
treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) regimen (and radiotherapy if applicable)
all stages (Ann Arbor I - IV)
Written informed consent
Patient affiliated or beneficiary of a benefit system
untreated patient (no corticosteroids or chemotherapy)

Critères de non-inclusion : No informed consent
Treatment by ABVD or BEACOPP not indicated
Previously treated Hodgkin lymphoma (including corticosteroids)
Patients who are pregnant or lactating
Active Hepatitis B or Hepatitis C infection
Known human immunodeficiency virus (HIV) infection - Patient with no social protection
Patient under tutorship or curatorship
Patient not affiliated of beneficiary of a benefit system
Medical contraindication to PET/CT
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT02815137
Promoteur :
Centre Henri Becquerel
Type de sponsor : Institutionnel
1, rue d'Amiens
76000 ROUEN

Coordonnateur :
Dr Fabrice JARDIN
fabrice.jardin@chb.unicancer.fr
+33232082465
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Henri Becquerel - Rue d'Amiens CS 11516 - Cedex 1 - 76000 ROUEN

Investigateur :
Fabrice JARDIN

TEC / ARC / IDE :
Justine LORET
justine.loret@
chb.unicancer.fr
02.32.08.30.45

Statut de l'essai : OUVERT

MAJ : 24/01/2020